Snake venom: A potent anticancer agent

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 4855-4860

  Jain, Deepika ^a   Kumar, Sudhir ^a  

^a IGNOU I2IT Centre of Excellence for Advanced Education and Research   (India)

Author keywords

Chemotherapy; Hormonal therapy; Immunotherapy; Radiation therapy; Toxins; Venoms

Indexed keywords

EID: 84874015091     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.4855     Document Type: Short Survey

References (45)

1. AAl-Sadoon MK, Abdel-Maksoud MA, Rabah DM, Badr G (2012). Induction of apoptosis and growth arrest in human breast carcinoma cells by a snake (walterinnesia aegyptia ) venom combined with silica nanoparticles: crosstalk between Bcl2 and Caspase 3. Cell Physiol Biochem, 30, 653-65.
2. Arimura T, Niwa K, Mitani N, et al (1989). A resected case of triple cancer in the uterus, lung and thyroid. Zasshi J: Nihon Kyobu Geka Gakkai, 37, 1233-7.
3. Armugam A, Cher CD, Lim K, et al (2009). A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis. BMC Neuroscience, 10, 120.
4. Barnett GC, West CM, Dunning AM, et al (2009). Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nature Rev Cancer, 9, 134-42.
5. Baskar R, Lee KA, Yeo R, Yeoh KW (2012). Cancer and radiation therapy: current advances and future directions. Int J Med Sci, 9, 193-9.
6. Bazaa A, Pasquier E, Defilles C, et al (2010). MVL-PLA2, a snakevenom phospholipase A2, inhibits angiogenesis through an increase in microtubule dynamics and disorganization of focal adhesions. PloS One, 5, e10124.
7. Berzofsky JA, Terabe M, Wood LV (2012). Strategies to use immune modulators in therapeutic vaccines against cancer. Seminars Oncol, 39, 348-57.
8. Bradbury MW, Deane R (1993). Permeability of the blood-brain barrier to lead. Neurotoxicology, 14, 131-6.
9. Chien CM, Yang SH, Chang LS, Lin SR (2008). Involvement of both endoplasmic reticulum- and mitochondria-dependent pathways in cardiotoxin III-induced apoptosis in HL-60 cells. Clin and Experimental Pharmacology and Physiology, 35, 1059-64.
10. Chien CM, Yang SH, Yang CC, et al (2008). Cardiotoxin III induces c-jun N-terminal kinase-dependent apoptosis in HL-60 human leukaemia cells. Cell Biochemistry and Function, 26, 111-8.
11. Chiu CC, Lin KL, Chien CM, et al (2009). Effects of cardiotoxin III on NF-kappaB function, proliferation, and apoptosis in human breast MCF-7 cancer cells. Oncol Res, 17, 311-21.
12. Cohen O, Kronman C, Chitlaru T, et al (2001). Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity. The Biochem J, 357, 795-802.
13. Costa LA, Miles HA, Diez RA, et al (1997). Phase I study of VRCTC-310, a purified phospholipase A2 purified from snake venom, in patients with refractory cancer: safety and pharmacokinetic data. Anti-Cancer Drugs, 8, 829-34.
14. Cura JE, Blanzaco DP, Brisson C, et al (2002). Phase I and pharmacokinetics study of crotoxin (Cytotoxic PLA2, NSC-624244) in Patients with advanced cancer. Clin Cancer Res, 8, 1033-41.
15. Debnath A, Chatterjee U, Das M, et al (2007). Venom of Indian monocellate cobra and Russell's viper show anticancer activity in experimental models. J Ethnopharmacology, 111, 681-4.
16. Escalante T, Ortiz N, Rucavado A, et al (2011). Role of collagens and perlecan in microvascular stability: exploring the mechanism of capillary vessel damage by snake venom metalloproteinases. PloS one, 6, 28017.
17. Faure G, Harvey AL, Thomson E, et al (1993). Comparison of crotoxin isoforms reveals that stability of the complex plays a major role in its pharmacological action. Eur J Biochem, 214, 491-6.
18. Ferrer (2001). Snake venom: The pain and potential of the venom. The cold blooded news, 28, PAGE?.
19. Gao W, Starkov VG, Tsetlin VI, et al (2005). Isolation and preliminary crystallographic studies of two new phospholipases A2 from vipera nikolskii venom. Acta crystallographica Ssection F, Structural Biol and Crystallization Commun, 61, 189-92.
20. Geissler M, Weth R (2002). (Immunotherapy: new insights). Praxis, 91, 2236-46.
21. Gomes A, Bhattacharjee P, Mishra R, et al (2010). Anticancer potential of animal venoms and toxins. Indian J Exp Biol, 48, 93-103.
22. Gomes A, Choudhury SR, Saha A, et al (2007). A heat stable protein toxin (drCT-I) from the Indian Viper (Daboia russelli russelli) venom having antiproliferative, cytotoxic and apoptotic activities. Toxicon: Official J Int Society on Toxinology, 49, 46-56.
23. Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P (2011). Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy, 31, 813-28.
24. Kang IC, Lee YD, Kim DS (1999). A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res, 59, 3754-60.
25. Kang TS, Georgieva D, Genov N, et al (2011). Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis. FEBS J, 278, 4544-76.
26. Kemparaju K, Girish KS (2006). Snake venom hyaluronidase: a therapeutic target. Cell Biochem Function, 24, 7-12.
27. Kruger C, Greten TF, Korangy F (2007). Immune based therapies in cancer. Histology Histopathology, 22, 687-96.
28. Lai D, Visser-Grieve S, Yang X (2012). Tumour suppressor genes in chemotherapeutic drug response. Biosci Reports, 32, 361-74.
29. Lin KL, Su JC, Chien CM, et al (2010). Down-regulation of the JAK2/PI3K-mediated signaling activation is involved in Taiwan cobra cardiotoxin III-induced apoptosis of human breast MDA-MB-231 cancer cells. Toxicon : Official J Int Society on Toxinology, 55, 1263-73.
30. Lokeshwar VB, Selzer MG (2008). Hyalurondiase: both a tumor promoter and suppressor. Seminars in Cancer Biol, 18, 281-7.
31. Markland FS, Shieh K, Zhou Q, et al (2001). A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model. Haemostasis, 31, 183-91.
32. Newman RA, Vidal JC, Viskatis LJ, et al (1993). VRCTC-310-a novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity. Invest New Drugs, 11, 151-9.
33. Orentas RJ, Lee DW, Mackall C (2012). Immunotherapy targets in pediatric cancer. Frontiers in Oncol, 2, 3.
34. Panfoli I, Calzia D, Ravera S, Morelli A (2010). Inhibition of hemorragic snake venom components: old and new approaches. Toxins, 2, 417-27.
35. Pawelek PD, Cheah J, Coulombe R, et al (2000). The structure of L-amino acid oxidase reveals the substrate trajectory into an enantiomerically conserved active site. The EMBO J, 19, 4204-15.
36. Rodrigues RS, Izidoro LF, de Oliveira RJ, et al (2009). Snake venom phospholipases A2: a new class of antitumor agents. Protein and Peptide Letters, 16, 894-8.
37. Rudd CJ, Viskatis LJ, Vidal JC, Etcheverry MA (1994). In vitro comparison of cytotoxic effects of crotoxin against three human tumors and a normal human epidermal keratinocyte cell line. Invest New Drugs, 12, 183-4.
38. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA: A Cancer J for Clin, 62, 10-29.
39. Song JK, Jo MR, Park MH, et al (2012). Cell growth inhibition and induction of apoptosis by snake venom toxin in ovarian cancer cell via inactivation of nuclear factor kappaB and signal transducer and activator of transcription 3. Archives of Pharmacal Res, 35, 867-76.
40. Su JC, Lin KL, Chien CM, et al (2010). Concomitant inactivation of the epidermal growth factor receptor, phosphatidylinositol 3-kinase/Akt and Janus tyrosine kinase 2/signal transducer and activator of transcription 3 signalling pathways in cardiotoxin III-treated A549 cells. Clin and Experimental Pharmacology and Physiology, 37, 833-40.
41. Tang N, Xie Q, Wang X, et al (2011). Inhibition of invasion and metastasis of MHCC97H cells by expression of snake venom cystatin through reduction of proteinases activity and epithelial-mesenchymal transition. Archives of Pharmacal Res, 34, 781-9.
42. Wei JF, Wei XL, Mo YZ, He SH (2009). Induction of mast cell accumulation, histamine release and skin edema by N49 phospholipase A2. BMC Immunol 10, 21.
43. Yang SH, Chien CM, Chang LS, Lin SR (2008). Cardiotoxin III-induced apoptosis is mediated by Ca2+-dependent caspase-12 activation in K562 cells. J Biochem And Molecular Toxicology, 22, 209-18.
44. Yang SH, Chien CM, Lu MC, et al (2006). Up-regulation ofBax and endonuclease G, and down-modulation of Bcl-XL involved in cardiotoxin III-induced apoptosis in K562 cells. Experimental & Molecular Med, 38, 435-44.
45. Yang SH, Chien CM, Lu MC, et al (2005). Cardiotoxin III induces apoptosis in K562 cells through a mitochondrial-mediated pathway. Clin and Experimental Pharmacology & Physiology, 32, 515-20.